Braemar Hotels & Resorts (BHR) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
3 Mar, 2026Executive summary
Initiated a sale process for the company in August 2025, engaging advisors to explore company and asset sales, and completed the sale of The Clancy in San Francisco for $115 million.
Portfolio delivered 1.8% growth in comparable total revenue for Q4 2025, with resorts driving strong performance and urban hotels underperforming.
Significant renovations at multiple hotels impacted results, but excluding these, RevPAR growth was 2.6% and Hotel EBITDA increased 6.4%.
Resort properties outperformed, with Q4 resort RevPAR up 4.1% and urban RevPAR down 10.1%.
Adjusted funds from operations (AFFO) per diluted share was $(0.02) for Q4 2025.
Financial highlights
Q4 2025 net loss attributable to common stockholders was $46 million ($0.67 per diluted share); AFFO per diluted share was $(0.02).
Full year 2025 net loss was $72.7 million ($1.07 per diluted share); AFFO per diluted share was $0.28.
Adjusted EBITDAre was $28.8 million for Q4 and $147 million for the full year; Comparable Hotel EBITDA was $38.0 million for Q4 and $164.2 million for the year.
Q4 Comparable ADR increased 5.4% to $559, but occupancy fell to 60.8%.
Q4 capex was $23.4 million; full-year capex was $77.9 million.
Outlook and guidance
Expect continued strong performance from recently renovated properties and ongoing focus on deleveraging and cash flow improvement.
Industry forecasts for 2026 project continued RevPAR growth in luxury and upper upscale segments, with luxury RevPAR expected to rise 2.5%.
No common equity dividend policy declared for 2026 due to the ongoing sale process.
Latest events from Braemar Hotels & Resorts
- Urban hotels outperformed as asset sales and refinancing strengthened the balance sheet.BHR
Q2 20242 Feb 2026 - Urban hotels outperformed as asset sales and refinancing strengthened liquidity.BHR
Q3 202415 Jan 2026 - Luxury hotel REIT expects higher cash flow and rates as supply tightens and demand rebounds.BHR
Sidoti Micro-Cap Virtual Conference9 Jan 2026 - Virtual annual meeting faces legal challenge over board nominations and voting procedures.BHR
Proxy Filing8 Dec 2025 - Q4 RevPAR rose 1.9% with strong bookings; 2025 outlook remains positive.BHR
Q4 20243 Dec 2025 - Board urges support for its nominees and proposals amid proxy contest and governance focus.BHR
Proxy Filing1 Dec 2025 - Proxy campaign targets board nominees as annual meeting approaches, highlighting governance and risk.BHR
Proxy Filing1 Dec 2025 - Proxy campaign opposes Blackwells' nominees and outlines key risks ahead of July 2024 vote.BHR
Proxy Filing1 Dec 2025 - Annual meeting to vote on directors, pay, auditor, and review a potential company sale.BHR
Proxy Filing1 Dec 2025